Integrating Bispecific Antibodies Into Clinical Practice
Panelists discuss how bispecifics, like teclistamab, are administered at their institutions, the monitoring of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) during step-up dosing, and strategies to improve care transitions between academic centers and community practices. They also highlight the potential for outpatient administration of bispecifics, as seen in the OPTec and Ambulatory Teclistamab studies, emphasizing the benefits of patient convenience and safety.
Video content above is prompted by the following:
- How is the step-up and treatment doses for bispecifics administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for CRS and ICANS during step-up doing?
- How can we improve the transition of care for patients receiving bispecifics between academic centers and community practices?
- Please comment on the following studies examining outpatient administration of bispecifics and how these strategies might be incorporated in practice: OPTec: Outpatient Step Up Administration of Teclistamab and Ambulatory Teclistamab Administration in R/R MM
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
